Breaking News Instant updates and real-time market news.

PX

Praxair

$122.18

3.49 (2.94%)

, LNEGY

Linde

$16.88

0.97 (6.10%)

16:18
11/29/16
11/29
16:18
11/29/16
16:18

On The Fly: Top stock stories for Tuesday

Stocks began the session in quiet fashion and remained range-bound throughout the day. Despite a much better than expected consumer confidence reading and an upward revision to the third quarter GDP estimate, the market was unable to generate any upside momentum. Even with today's tepid action, the market is on pace to close out November with solid gains on the back of the post-election rally that has just been paused over the last two sessions. ECONOMIC NEWS: In the U.S., third quarter GDP growth was upwardly revised to a 3.2% annual rate from the previously reported estimate of a 2.9% pace, helped by a big service-led boost to consumption and a smaller than expected downward inventory adjustment. The Case Shiller home price index rose 0.13% to 191.78 in September for the 20-city index, after a 0.38% gain in August. Consumer confidence surged 6.3 points to 107.1 in November, which was better than expected. According to data compiled by Adobe Digital Insights, shoppers spent $3.45B on Cyber Monday, marking the largest online sales day in U.S. history and easily surpassing prior estimates. In Asia, Japan's unemployment rate came in at 3% in October, unchanged from the previous month. Japan's retail sales fell 0.1% from a year before. In Europe, German consumer prices rose 0.1% in November. COMPANY NEWS: Shares of Tiffany & Co. (TIF) gained a bit over 3% after the company's third quarter results exceeded analysts' expectations, though the luxury jeweler said it needs to see more positive data before considering the quarter "an inflection point"... Shares of UnitedHealth Group (UNH) advanced 3.6% after the company backed its fiscal 2016 guidance and provided better than expected guidance for fiscal 2017... Praxair (PX) has approached Linde (LNEGY) in an effort to restart talks over a potential tie-up that would create a $60B industrial-gas giant, the Wall Street Journal reported. Linde subsequently confirmed the report, saying that it has received a revised proposal that is being reviewed by its Executive Board. Praxair, which also confirmed that the company has approached Linde about resuming discussions regarding a potential merger, rose about 3% following the news. MAJOR MOVERS: Among the notable gainers was Thor Industries (THO), which advanced 12.6% after reporting better than expected first quarter results. Also higher was WGL Holdings (WGL), which gained 9% after Bloomberg reported that the company is considering options, including a potential sale, after drawing takeover interest from Spain's Iberdrola (IBDRY). Additionally, Alexion (ALXN) rose a bit over 5% after Barclays analyst Geoff Meacham upgraded the stock to Overweight as he sees fewer macro headwinds and expects approval of Soliris in refractory gMG by year-end 2017, which could add to growth in early 2018. Among the noteworthy losers was Amicus Therapeutics (FOLD), which dropped nearly 22% after ruling out accelerated approval for its migalastat product and confirming the need for additional data following its consultation with the FDA. Also lower was Mallinckrodt (MNK), which fell 9% despite announcing better than expected fourth quarter adjusted earnings per share and revenue. Additionally, Delphi Automotive (DLPH) dropped over 4% after Morgan Stanley analyst Adam Jonas downgraded the stock to Underweight as he believes an acceleration of electric vehicle strategy by the company's OEM customers will negatively impact growth and result in greater up-front R&D costs. INDEXES: The Dow rose 23.70, or 0.12%, to 19,121.60, the Nasdaq gained 11.11, or 0.21%, to 5,379.92, and the S&P 500 advanced 2.94, or 0.13%, to 2,204.66.

PX

Praxair

$122.18

3.49 (2.94%)

LNEGY

Linde

$16.88

0.97 (6.10%)

TIF

Tiffany

$80.60

2.46 (3.15%)

UNH

UnitedHealth

$157.59

5.48 (3.60%)

THO

Thor Industries

$101.84

11.4 (12.61%)

WGL

WGL Holdings

$75.21

6.19 (8.97%)

IBDRY

Iberdrola

$24.32

0.195 (0.81%)

ALXN

Alexion

$125.59

6.21 (5.20%)

FOLD

Amicus

$6.51

-1.81 (-21.75%)

MNK

Mallinckrodt

$52.42

-5.25 (-9.10%)

DLPH

Delphi

$63.44

-2.88 (-4.34%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 14

    Dec

  • 10

    Jan

PX Praxair
$122.18

3.49 (2.94%)

03/24/16
FBCO
03/24/16
NO CHANGE
Target $117
FBCO
Neutral
Praxair assumed with a Neutral at Credit Suisse
Credit Suisse analyst Christopher Parkinson assumed coverage on Praxair with a Neutral rating and increased the price target to $117 from $107.
04/04/16
DBAB
04/04/16
DOWNGRADE
Target $120
DBAB
Hold
Praxair downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst David Begleiter downgraded Praxair to Hold but raised his price target for the shares to $120 from $114.
02/02/16
02/02/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Agnico Eagle (AEM) downgraded to Hold from Buy at Desjardins... Alere (ALR) downgraded to Hold from Buy at Canaccord... Antero Resources (AR) downgraded to Reduce from Neutral at SunTrust... Carbylan (CBYL) downgraded to Market Perform from Outperform at Leerink... Copa Holdings (CPA) downgraded to Hold from Buy at Deutsche Bank... Dominion (D) downgraded to Neutral from Buy at Citi... Duke Energy (DUK) downgraded to Market Perform from Outperform at Wells Fargo... Hain Celestial (HAIN) downgraded to Neutral from Overweight at Piper Jaffray... Integrated Device (IDTI) downgraded to Neutral from Buy at BofA/Merrill... Logitech (LOGI) downgraded to Underweight from Equal Weight at Morgan Stanley... Merus Labs (MSLI) downgraded to Sector Perform from Outperform at Scotiabank... New Gold (NGD) downgraded to Sell from Buy at Desjardins... Nokia (NOK) downgraded to Underperform from Buy at CLSA... Plantronics (PLT) downgraded to Underperform from Outperform at Raymond James... Pool Corp. (POOL) downgraded to Equal Weight from Overweight at Stephens... Praxair (PX) downgraded to Sector Weight from Overweight at KeyBanc... Rofin-Sinar (RSTI) downgraded to Neutral from Buy at Longbow... Southwestern Energy (SWN) downgraded to Neutral from Overweight at JPMorgan... Stifel cuts Twitter (TWTR) to Sell after noting Yahoo has significantly more users... Superior Energy (SPN) downgraded to In-Line from Outperform at Imperial Capital... Sysco (SYY) downgraded to Underweight from Equal Weight at Morgan Stanley... Telenor (TELNY) downgraded to Underperform from Neutral at Credit Suisse... Twitter (TWTR) downgraded to Sell from Hold at Stifel... Valeo (VLEEY) downgraded to Underweight from Equal Weight at Morgan Stanley.
08/16/16
JEFF
08/16/16
NO CHANGE
Target $140
JEFF
Buy
Jefferies sees 20% probability of Praxair, Linde merger
Following the Wall Street Journal's report last night, Jefferies analyst Laurence Alexander pegs a potential merger between Praxair (PX) and Linde (LNEGY) at 20%. The analyst estimates Praxair could pay a 26% control premium, 50% equity, and still achieve an 8% return on invested capital in the third year and improve free cash flow per share by $1.70. Alexander has a Buy rating on Praxair with a $140 price target.
LNEGY Linde
$16.88

0.97 (6.10%)

09/05/16
SBSH
09/05/16
UPGRADE
SBSH
Neutral
Linde upgraded to Neutral from Sell at Citi
09/13/16
SBSH
09/13/16
DOWNGRADE
SBSH
Sell
Linde downgraded to Sell from Neutral at Citi
TIF Tiffany
$80.60

2.46 (3.15%)

11/14/16
JEFF
11/14/16
NO CHANGE
Target $100
JEFF
Buy
Tiffany price target raised to $100 from $85 at Jefferies
Jefferies analyst Randal Konik raised his price target for Tiffany to $100 saying the company has a strong positioning in a growing market. Fashion jewelry fundamentals are improving while tourism headwinds are abating, Konik tells investors in a research note. The analyst reiterates a Buy rating on the shares.
11/29/16
SBSH
11/29/16
NO CHANGE
Target $79
SBSH
Neutral
Citi keeps Neutral on Tiffany despite improvements in Q3
Citi analyst Paul Lejuez says that while Tiffany's Q3 results showed signs of improvement, he remains concerned over the company's ability to connect with the millennial customer in the U.S. He also believes the recent strengthening of the U.S. dollar could act as a headwind to Q4 and FY17. Lejuez expects Tiffany shares to trade higher today but he keeps a Neutral rating on the name with a $79 price target.
11/17/16
JEFF
11/17/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies sees 'robust' traffic at Tiffany flagship store amid Trump protests
After spending three days monitoring Tiffany's 5th Avenue flagship store in Manhattan to gauge traffic patterns and any Trump Tower protest related issues, Jefferies analyst Randal Konik concluded the store's traffic "was robust, not weak." Street police activity was high but didn't inhibit entrance to the store, Konik tells investors in a research note titled "5th Ave Flagship Store Checks Over Three Days Show 'Huuuuge' Strength." He believes investors are concerned that protests surrounding Trump Tower and high security will disrupt Tiffany's 5th Avenue store business. Konik keeps a Buy rating on Tiffany with a $100 price target.
11/23/16
OPCO
11/23/16
NO CHANGE
Target $87
OPCO
Outperform
Tiffany price target raised to $87 from $80 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Tiffany to $87 from $80 ahead of results. While the analyst is concerned that a still challenged sales backdrop and higher expenses could weigh on results, longer term he is increasingly optimistic that internal merchandising and marketing efforts have the potential to fuel improved results, particularly as macro pressures potentially subside. Nagel reiterates an Outperform rating on the shares.
UNH UnitedHealth
$157.59

5.48 (3.60%)

11/09/16
MZHO
11/09/16
DOWNGRADE
Target $135
MZHO
Neutral
UnitedHealth downgraded to Neutral on Republican win at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded UnitedHealth to Neutral from Buy citing Donald Trump's election and the move to a GOP Congress. Following the election results, Skolnick sees an "extreme risk" for the ACA to be repealed and replaced and for the loss of the Medicaid expansion, both of which she notes have been primary drivers of results for hospitals and health plans. She cut her price target on the stock to $135 from $169.
11/09/16
MZHO
11/09/16
DOWNGRADE
MZHO
Neutral
UnitedHealth downgraded to Neutral from Buy at Mizuho
10/19/16
LEER
10/19/16
NO CHANGE
Target $175
LEER
Outperform
UnitedHealth price target raised to $175 from $165 at Leerink
Leerink analyst Ana Gupte raised her price target for UnitedHealth to $175 from $165 after the company reported a "solid beat and raise" Q3, giving her more confidence in the strength of the company's diversified platform and execution while also offering positive read-across for Commercial Fully Insured & Individual fundamentals to the rest of the group. The analyst reiterates an Outperform rating on the shares.
11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
THO Thor Industries
$101.84

11.4 (12.61%)

07/29/16
RHCO
07/29/16
UPGRADE
RHCO
Buy
Thor Industries upgraded on multiple catalysts at SunTrust
As noted earlier, SunTrust upgraded Thor to Buy from Neutral. Analyst Michael Swartz predicts that the company will benefit from higher than expected accretion and synergies from its Jayco acquisition, as well as 20%-40% growth in industry volumes by 2020. Target $90.
09/28/16
WLSD
09/28/16
UPGRADE
WLSD
Buy
Thor Industries upgraded to Buy from Gradually Accumulate at Wellington Shields
09/13/16
NRCS
09/13/16
UPGRADE
Target $95
NRCS
Buy
Thor Industries upgraded to Buy from Neutral at Northcoast
Northcoast analyst Seth Woolf upgraded Thor Industries to Buy with a $95 price target. The analyst said the recent move in shares still doesn't reflect full accretion of the Jayco acquisition nor the strategic benefits. Woolf believes that the Jayco deal gives the company the best product portfolio in the industry. This is particularly true as it relates to Thor's ability to ride the wave of younger consumers entering the channel via entry-level travel trailers, the analyst wrote.
08/19/16
WDLK
08/19/16
DOWNGRADE
Target $80
WDLK
Hold
Thor Industries downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Rommel Dionisio downgraded Thor Industries to Hold citing the recent rally in the shares. The analyst keeps an $80 price target for the name.
WGL WGL Holdings
$75.21

6.19 (8.97%)

01/06/16
01/06/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Arista Networks (ANET) initiated with a Neutral at UBS... Cerulean (CERU) initiated with a Buy at Janney Capital... Codexis (CDXS) initiated with a Buy at H.C. Wainwright... Colgate-Palmolive (CL) initiated with an Overweight at Atlantic Equities... Danone (DANOY) initiated with a Buy at HSBC... Demandware (DWRE) initiated with a Buy at BofA/Merrill... Diplomat Pharmacy (DPLO) initiated with an Overweight at Barclays... Edwards Lifesciences (EW) initiated with an Outperform at JMP Securities... Enterprise Products (EPD) initiated with an Outperform at Scotia Howard Weil... Green Brick (GRBK) initiated with a Market Perform at JMP Securities... Hoegh LNG (HMLP) initiated with an Accumulate at Seaport Global... Idera Pharmaceuticals (IDRA) initiated with an Outperform at Wedbush... Jack in the Box (JACK) initiated with a Neutral at SunTrust... New Jersey Resources (NJR) initiated with a Market Perform at Wells Fargo... Novadaq (NVDQ) initiated with an Outperform at JMP Securities... Ollie's Bargain Outlet (OLLI) initiated with a Buy at Johnson Rice... Procter & Gamble (PG) initiated with a Neutral at Atlantic Equities... Shake Shack (SHAK) initiated with a Neutral at SunTrust... Steel Dynamics (STLD) initiated with a Buy at Rosenblatt... Teladoc (TDOC) initiated with a Hold at Stifel... TripAdvisor (TRIP) initiated with a Neutral at Hilliard Lyons... Tyco (TYC) initiated with a Neutral at Buckingham... WGL Holdings (WGL) initiated with a Market Perform at Wells Fargo... Willis Towers Watson (WLTW) initiated with an Outperform at William Blair... bluebird bio (BLUE) initiated with a Buy at Janney Capital.
11/18/16
JANY
11/18/16
UPGRADE
JANY
Buy
WGL Holdings upgraded to Buy from Neutral at Janney Capital
11/29/16
JANY
11/29/16
DOWNGRADE
Target $71
JANY
Neutral
WGL Holdings downgraded to Neutral from Buy at Janney Capital
Janney Capital analyst Michael Gaugler downgraded WGL Holdings to Neutral citing valuation after Bloomberg reported that the company is exploring a sale. The analyst has a $71 fair value estimate for the shares.
03/30/16
03/30/16
INITIATION

Hold
WGL Holdings initiated with a Hold at BB&T
IBDRY Iberdrola
$24.32

0.195 (0.81%)

09/07/16
GSCO
09/07/16
UPGRADE
GSCO
Buy
Iberdrola upgraded to Buy from Neutral at Goldman
ALXN Alexion
$125.59

6.21 (5.20%)

11/29/16
LEHM
11/29/16
UPGRADE
Target $155
LEHM
Overweight
Alexion upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Alexion to Overweight and raised its price target to $155 from $150. The analyst sees fewer macro headwinds and lower FX over the next 12 months and expects approval of Soliris in refractory gMG by year-end 2017, which could add to growth in early 2018.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
11/14/16
PIPR
11/14/16
NO CHANGE
Target $176
PIPR
Overweight
Piper sees 'sharp recovery' in Alexion shares
Piper Jaffray analyst Joshua Schimmer expects a "sharp recovery" in Alexion shares "if/when" the whistleblower case regarding sales practices of Soliris is resolved. The analyst still believes the case will likely to prove benign. He reiterates an Overweight rating on Alexion with a $176 price target.
11/11/16
11/11/16
NO CHANGE
Target $175

Buy
Alexion CFO reports 'no new news,' says Citi
As previously reported, Citi analyst Robin Karnauskas said the selloff in shares of Alexion is a buying opportunity. The company's CFO noted there have been no new disclosures today and repeated that Alexion is assisting with an investigation and cannot comment during that process, said the analyst, who keeps a Buy rating and $175 price target on the stock.
FOLD Amicus
$6.51

-1.81 (-21.75%)

11/29/16
COWN
11/29/16
NO CHANGE
Target $12
COWN
Outperform
Amicus price target lowered to $12 from $15 at Cowen
Cowen analyst Ritu Baral lowered her price target on Amicus to $12 from $15 after the FDA told the company it could not file the Galafold NDA with current data and that data from a new trial is expected in 2019. Baral maintained her Outperform rating on Amicus, stating that the planned GI trial has a good chance of success.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
07/20/16
JPMS
07/20/16
NO CHANGE
Target $13
JPMS
Overweight
Amicus risk/reward 'compelling' at current levels, says JPMorgan
JPMorgan analyst Anupam Rama views the risk/reward for shares of Amicus Therapeutics at current levels as "compelling." After declining 39% year-to-date, Amicus is essentially only pricing in outside the U.S. Galafold sales in Fabry disease plus cash, Rama tells investors in a research note. Very little credit is being given to the company's U.S. migalastat, Zorblisa or the Pompe program, which all have events in the second half of 2016, the analyst contends. Rama thinks only one of the three need to hit for the stock to trade "materially higher," with upside ranging from 20%-100%-plus on a single success, and "meaningfully more upside" potential on multiple positive updates. Rama reiterates an Overweight rating on Amicus with a $13 price target.
MNK Mallinckrodt
$52.42

-5.25 (-9.10%)

11/18/16
RAJA
11/18/16
INITIATION
Target $72
RAJA
Outperform
Mallinckrodt initiated with an Outperform and $72 price target at Raymond James
Raymond James analyst Elliot WIlbur initiated Mallinckrodt with an Outperform and a $72 price target saying negative sector sentiment combined with further allegations from short sellers have created a compelling entry point. Wilbur believes Mallinckrodt provides one of the most sustainable top and bottom line growth trajectories in specialty pharmaceuticals and notes Achar has only a 3% penetration rate of the total addressable market, giving it a long runway of growth.
11/17/16
RAJA
11/17/16
INITIATION
Target $72
RAJA
Outperform
Mallinckrodt initiated with an Outperform at Raymond James
Raymond James initiated Mallinckrodt with an Outperform and a $72 price target.
11/21/16
UBSW
11/21/16
NO CHANGE
Target $92
UBSW
Buy
Mallinckrodt weakness does not make sense, says UBS
UBS analyst Marc Goodman attended Mallinckrodt investors meetings and came away believing investors misunderstand the company story. The analyst said the company's Acthar drug, which has come under fire, has little relevance to the overall story. Goodman said the company has focused on enhancing clinical and health-economics data to help support better coverage and it is working. He said its emerging pipeline is under-appreciated. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
11/17/16
WELS
11/17/16
NO CHANGE
WELS
Outperform
Mallinckrodt drop on short-seller report a buying opportunity, says Wells Fargo
Wells Fargo analyst David Maris said the 12% drop in Mallinckrodt on the heels of a new report from short-seller Citron Research presents a buying opportunity, as he believes the assertion that Acthar has no clinical data is incorrect. Maris noted the report came out during Mallinckrodt's quiet period, which is something that had previously happened with a prior Citron report on the company, but the company tells him that the CEO's previous answer to a question regarding Acthar's exposure to Medicaid and Medicare was accurate. Maris keeps an Outperform rating on Mallinckrodt shares.
DLPH Delphi
$63.44

-2.88 (-4.34%)

11/22/16
BREN
11/22/16
INITIATION
Target $70
BREN
Hold
Delphi initiated with a Hold at Berenberg
Target $70.
11/09/16
11/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) downgraded to Neutral from Outperform at Baird with analyst David George noting the stock's outperformance and the higher re-rating of its valuation multiple. 2. GoPro (GPRO) downgraded to Neutral from Outperform at Wedbush, to Market Perform from Outperform at Raymond James, and to Sell from Neutral at Dougherty. 3. Universal Health (UHS) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Mizuho, and to Market Perform from Outperform at Avondale. 4. Globus Medical (GMED) downgraded to Market Perform from Outperform at JMP Securities, to Perform from Outperform at Oppenheimer, and to Market Perform from Outperform at William Blair. 5. Delphi (DLPH) and Magna (MGA) were downgraded to Underperform from Buy at BofA/Merrill while the firm downgraded Lear (LEA), American Axle (AXL), Adient (ADNT), and BorgWarner (BWA) to Underperform from Neutral. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/16
MSCO
11/29/16
DOWNGRADE
MSCO
Underweight
Delphi downgraded to Underweight from Equal Weight at Morgan Stanley
11/29/16
11/29/16
DOWNGRADE
Target $59

Underweight
Delphi downgraded to Underweight on electrification risk at Morgan Stanley
As previously reported, Morgan Stanley downgraded Delphi to Underweight from Equal Weight and lowered its price target to $59 from $75. Analyst Adam Jonas believes an acceleration of electric vehicle strategy by Delphi's OEM customers will negatively impact growth, lower margins for ICE powertrain, and result in greater up-front RD&E costs. The analyst sees diminishing economic returns given changing OEM priorities to re-engineer propulsion systems to electric from internal combustion, creating material earnings growth risk.

TODAY'S FREE FLY STORIES

SWKS

Skyworks

$74.82

1.48 (2.02%)

11:00
12/06/16
12/06
11:00
12/06/16
11:00
Options
Nice timing of an early sweep in Weekly options on Skyworks Solutions »

Nice timing of an early…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

PAVM

PAVmed

10:59
12/06/16
12/06
10:59
12/06/16
10:59
Conference/Events
PAVmed to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

HAR

Harman

$109.79

0.125 (0.11%)

10:57
12/06/16
12/06
10:57
12/06/16
10:57
Hot Stocks
Breaking Hot Stocks news story on Harman »

JP Morgan lowers passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 10

    Jan

BWA

BorgWarner

$38.48

0.99 (2.64%)

10:56
12/06/16
12/06
10:56
12/06/16
10:56
Technical Analysis
BorgWarner moves higher, potential bullish pattern »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

EC

Ecopetrol

$8.74

0.14 (1.63%)

10:56
12/06/16
12/06
10:56
12/06/16
10:56
Recommendations
Ecopetrol analyst commentary  »

Ecopetrol added to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

10:55
12/06/16
12/06
10:55
12/06/16
10:55
Hot Stocks
Google Wifi now available for purchase »

According to an email by…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

VLKAY

Volkswagen

$27.98

0.8 (2.94%)

10:55
12/06/16
12/06
10:55
12/06/16
10:55
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Oversight &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 05

    Jan

  • 10

    Jan

BOBE

Bob Evans

$46.77

1.05 (2.30%)

, JPM

JPMorgan

$82.99

-0.27 (-0.32%)

10:51
12/06/16
12/06
10:51
12/06/16
10:51
Hot Stocks
Bob Evans holder Sandell 'encouraged' by retention of financial advisor »

Sandell Asset Management,…

BOBE

Bob Evans

$46.77

1.05 (2.30%)

JPM

JPMorgan

$82.99

-0.27 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

ETE

Energy Transfer Equity

$16.24

0.17 (1.06%)

10:50
12/06/16
12/06
10:50
12/06/16
10:50
Options
Notable call spreads in Energy Transfer Equity »

Notable call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$60.22

0.97 (1.64%)

, LNKD

LinkedIn

$195.41

0.16 (0.08%)

10:49
12/06/16
12/06
10:49
12/06/16
10:49
Hot Stocks
European Commission approves acquisition of LinkedIn by Microsoft »

The European Commission…

MSFT

Microsoft

$60.22

0.97 (1.64%)

LNKD

LinkedIn

$195.41

0.16 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BW

Babcock & Wilcox

$16.02

0.03 (0.19%)

10:47
12/06/16
12/06
10:47
12/06/16
10:47
Conference/Events
Babcock & Wilcox management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RIG

Transocean

$14.13

0.15 (1.07%)

10:47
12/06/16
12/06
10:47
12/06/16
10:47
Hot Stocks
Transocean announces approval of merger with Transocean Partners »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

$27.90

0.2 (0.72%)

10:46
12/06/16
12/06
10:46
12/06/16
10:46
Conference/Events
Werner management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SNN

Smith & Nephew

$28.77

0.27 (0.95%)

10:46
12/06/16
12/06
10:46
12/06/16
10:46
Conference/Events
Smith & Nephew management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RP

RealPage

$28.80

0.25 (0.88%)

10:45
12/06/16
12/06
10:45
12/06/16
10:45
Conference/Events
RealPage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

10:45
12/06/16
12/06
10:45
12/06/16
10:45
General news
The U.S. factory goods data slightly underperformed »

The U.S. factory goods…

BAC

Bank of America

$21.81

-0.03 (-0.14%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Hot Stocks
Bank of America CEO: $53B cost-cutting target reflects 'environment we're in' »

Says "tremendous…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Jan

RP

RealPage

$28.80

0.25 (0.88%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Conference/Events
RealPage management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

MMI

Marcus & Millichap

$27.72

-0.1 (-0.36%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Conference/Events
Marcus & Millichap management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

IT

Gartner

$101.15

0.46 (0.46%)

10:43
12/06/16
12/06
10:43
12/06/16
10:43
Conference/Events
Gartner management to meet with William Blair »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

HIBB

Hibbett Sports

$42.55

2.1 (5.19%)

10:42
12/06/16
12/06
10:42
12/06/16
10:42
Conference/Events
Hibbett Sports management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

ISRG

Intuitive Surgical

$636.95

0.31 (0.05%)

10:42
12/06/16
12/06
10:42
12/06/16
10:42
Technical Analysis
Intuitive Surgical falls, levels to watch »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

AOSL

Alpha & Omega

$20.51

0.43 (2.14%)

10:40
12/06/16
12/06
10:40
12/06/16
10:40
Conference/Events
Alpha & Omega management to meet with Drexel Hamilton »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SBUX

Starbucks

$57.50

0.29 (0.51%)

10:40
12/06/16
12/06
10:40
12/06/16
10:40
Options
Option action heats up in Starbuck's weeklys »

Option action heats up in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AIRM

Air Methods

$32.70

0.15 (0.46%)

10:39
12/06/16
12/06
10:39
12/06/16
10:39
Conference/Events
Air Methods management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.